Longboard Pharmaceuticals... (LBPH)
NASDAQ: LBPH
· Real-Time Price · USD
59.98
null (null%)
At close: Nov 29, 2024, 7:00 PM
Longboard Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 2K | 1K | 1K | 1K | 2K | 1K | 1K | 1K | 2K | 1K | 1K | n/a | n/a | n/a |
Gross Profit | n/a | -2K | -1K | 7K | -1K | -2K | -1K | -1K | -1K | -2K | -1K | -1K | n/a | n/a | n/a |
Operating Income | -28.12M | -25.64M | -18.11M | -15.57M | -13.58M | -15.64M | -11.96M | -11.73M | -11.88M | -11.57M | -9.62M | -8.79M | -6.36M | -6.99M | -5.7M |
Interest Income | 3.65M | 3.9M | 3.13M | 567K | 662K | 660K | 516K | 391K | 287K | 127K | 32K | 24K | 23K | 13K | 4K |
Pretax Income | -24.54M | -21.79M | -14.99M | -15.03M | -12.93M | -15M | -11.46M | -11.35M | -11.6M | -11.41M | -9.6M | -8.77M | -6.34M | -6.98M | -5.7M |
Net Income | -24.54M | -21.79M | -14.99M | -15.03M | -12.93M | -15M | -10.95M | -10.96M | -11.31M | -11.41M | -9.6M | -8.77M | -6.34M | -6.98M | -5.7M |
Selling & General & Admin | 6.67M | 5.2M | 4.94M | 3.38M | 3.09M | 3.11M | 3.43M | 2.53M | 2.48M | 2.65M | 2.5M | 2.43M | 2.26M | 2.07M | 1.3M |
Research & Development | 21.45M | 20.45M | 13.17M | 12.2M | 10.49M | 12.54M | 8.53M | 9.19M | 9.4M | 8.92M | 7.12M | 6.37M | 4.09M | 4.92M | 4.4M |
Other Expenses | n/a | -47K | -9K | -27K | -14K | -17K | -10K | -9K | 1K | 33K | -9K | -3K | -13K | -6K | n/a |
Operating Expenses | 28.12M | 25.64M | 18.11M | 15.57M | 13.58M | 15.64M | 11.96M | 11.73M | 11.88M | 11.57M | 9.62M | 8.79M | 6.36M | 6.99M | 5.7M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 28.12M | 25.64M | 18.11M | 15.57M | 13.58M | 15.64M | 11.96M | 11.73M | 11.88M | 11.57M | 9.62M | 8.79M | 6.36M | 6.99M | 5.7M |
Income Tax Expense | n/a | -2K | -42.28K | n/a | -1K | n/a | -506K | -382K | -288K | n/a | -32K | -25K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 38.96M | 38.88M | 35.32M | 23.92M | 23.49M | 22.97M | 20.41M | 17.21M | 17.17M | 17.13M | 17.09M | 17.03M | 16.87M | 16.83M | 16.87M |
Shares Outstanding (Diluted) | 38.96M | 38.88M | 35.32M | 23.92M | 23.49M | 22.97M | 20.41M | 17.21M | 17.17M | 17.13M | 17.09M | 17.03M | 16.87M | 16.83M | 16.87M |
EPS (Basic) | -0.63 | -0.56 | -0.42 | -0.63 | -0.55 | -0.65 | -0.54 | -0.64 | -0.66 | -0.67 | -0.56 | -0.52 | -0.38 | -0.41 | -0.34 |
EPS (Diluted) | -0.63 | -0.56 | -0.42 | -0.63 | -0.55 | -0.65 | -0.54 | -0.64 | -0.66 | -0.67 | -0.56 | -0.52 | -0.38 | -0.41 | -0.34 |
EBITDA | -28.12M | -25.64M | -18.11M | -15.57M | -13.58M | -15.64M | -11.96M | -11.73M | -11.88M | -11.56M | -9.62M | -8.79M | -6.36M | -6.99M | -5.7M |
EBIT | -28.12M | -25.64M | -18.11M | -15.57M | -13.58M | -15.64M | -11.96M | -11.73M | -11.88M | -11.57M | -9.62M | -8.79M | -6.36M | -6.99M | -5.7M |
Depreciation & Amortization | 1K | 2K | 1K | 1K | 1K | 2K | 1K | 1K | 1K | 2K | 1K | 1K | 6.36M | 6.99M | 5.7M |